rusfertide
Peptide
Also known as TAK-121
Evidence outlook
Approved: Polycythemia Vera (label: Erythrocytosis in adults with polycythemia vera)
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Reliable signal
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
VERIFY NCT05210790 · Polycythemia Vera This was a randomized, triple-blind, placebo-controlled trial in 293 people, and rusfertide significantly increased the proportion who no longer qualified for phlebotomy (76.9% vs 32.9%, odds ratio 6.42, p<0.0001). A power calculation for this endpoint was reported, and enrolment exceeded the number it required. Registry: NCT05210790 | 3 | Part 1a: Percentage of Participants Who Achieved Response (From Weeks 20 to 32) 2025-02-21 | Response in weeks 20 to 32 (Part 1a): rusfertide 76.9% (n=147) vs placebo 32.9% (n=146), odds ratio 6.42 (95% CI 3.81 to 10.80), p<0.0001 (CT.gov posted results). | Reliable signal | link ↗ |
View 1 more trial
THRIVE NCT06033586 · Polycythemia Vera Registry: NCT06033586 | 3 | Hematocrit (0-2 years); Phlebotomies (0-2 years) 2026-04-01 | Results not posted; external-source review pending | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 3 (2)
What this study did
What this study did
Phase 2 (7)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1 (1)
What this study did
Competitive landscape
This drug's own stage for Polycythemia Vera: Approved. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Rusfertide: this drug | Approved | Peptide | Ferroportin | Reliable signal | NCT05210790: Response in weeks 20 to 32 (Part 1a): rusfertide 76.9% (n=147) vs placebo 32.9% (n=146), odds ratio 6.42 (95% CI 3.81 to 10.80), p<0.0001 (CT.gov posted results). | |
| Ropeginterferon Alfa-2b (Besremi) | Approved | Protein / enzyme therapeutic | Type I interferon receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Ruxolitinib (Jakafi) | Approved | Small molecule | JAK1/2 | Partial signal | NCT01243944: The Percentage of Participants Achieving a Primary Response at Week 32 (32 Weeks): Ruxolitinib 22.7 percentage of participants (95% CI 15.3 to 31.7) | Best Available Therapy 0.9 percentage of participants (95% CI 0 to 4.9) | |
| Givinostat | Phase 3 | Small molecule | HDAC | not yet graded | No reviewed efficacy summary in this indication | |
| DISC-3405 | Phase 2 | Monoclonal antibody | TMPRSS6 (matriptase-2) | not yet graded | No reviewed efficacy summary in this indication |
Upcoming events
(2 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow rusfertide to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
Regulatory and conference events
(3)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent